WO2017117636A1 - Système et procédé d'évaluation de l'état du sommeil - Google Patents

Système et procédé d'évaluation de l'état du sommeil Download PDF

Info

Publication number
WO2017117636A1
WO2017117636A1 PCT/AU2017/050015 AU2017050015W WO2017117636A1 WO 2017117636 A1 WO2017117636 A1 WO 2017117636A1 AU 2017050015 W AU2017050015 W AU 2017050015W WO 2017117636 A1 WO2017117636 A1 WO 2017117636A1
Authority
WO
WIPO (PCT)
Prior art keywords
sleep
individual
bks
score
time
Prior art date
Application number
PCT/AU2017/050015
Other languages
English (en)
Inventor
Malcolm Kenneth Horne
Original Assignee
Global Kinetics Corporation Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900036A external-priority patent/AU2016900036A0/en
Application filed by Global Kinetics Corporation Pty Ltd filed Critical Global Kinetics Corporation Pty Ltd
Priority to AU2017204960A priority Critical patent/AU2017204960A1/en
Priority to US16/068,183 priority patent/US20190008451A1/en
Priority to CN201780009611.4A priority patent/CN108697379A/zh
Priority to CA3010346A priority patent/CA3010346A1/fr
Priority to EP17735774.6A priority patent/EP3399912B1/fr
Priority to JP2018535025A priority patent/JP2019505291A/ja
Publication of WO2017117636A1 publication Critical patent/WO2017117636A1/fr
Priority to AU2021266231A priority patent/AU2021266231A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4806—Sleep evaluation
    • A61B5/4815—Sleep quality
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
    • A61B5/1118—Determining activity level
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4806—Sleep evaluation
    • A61B5/4809—Sleep detection, i.e. determining whether a subject is asleep or not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6802—Sensor mounted on worn items
    • A61B5/681—Wristwatch-type devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235—Details of waveform analysis
    • A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7278—Artificial waveform generation or derivation, e.g. synthesising signals from measured signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2505/00—Evaluating, monitoring or diagnosing in the context of a particular type of medical care
    • A61B2505/07—Home care
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02—Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0219—Inertial sensors, e.g. accelerometers, gyroscopes, tilt switches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4806—Sleep evaluation
    • A61B5/4812—Detecting sleep stages or cycles
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Definitions

  • the present invention relates to a system and method for monitoring or assessing a sleep state of an individual, and in particular to a system and method configured to monitor a kinetic state of the individual in order to assess sleep state.
  • Sleep disturbances can arise in many disorders, and for example are common in Parkinson's disease (PD). Fragmentation of sleep, characterized by repetitive short interruptions of sleep, is one important characteristic of sleep which can be assessed. Fragmented sleep may for example be caused by sleep apnoea, REM sleep disorders, restless legs, pain, nocturia, hallucinations and affective disorders. Sleep architecture, which refers to how an individual cycles through the stages of sleep, and sleep efficiency, being the percentage of time asleep, are also important characteristics of sleep.
  • PSG Polysomnography
  • measures such as sleep efficiency, Arousal index, Apnoea Hypopnea Index and Periodic Limb Movements per hour to generate a report that takes into account these scores.
  • PSG is the gold standard for sleep assessment but is heavily weighted to the assessment of apnoeas and has the disadvantage that it assesses sleep on a single night in conditions that are not typical for the patient.
  • sleep studies require the patient to spend a night sleeping in a clinical setting while being closely monitored, and are thus expensive, inconvenient and ill-suited to screening of large numbers of patients. In many countries or in remote areas, formal sleep studies are not even readily available.
  • Actigraphy has been attempted as a means to assess sleep in the home but has failed to accurately quantify sleep because it uses relatively unprocessed accelerometry and is thus overly affected by the limb movements of sleep.
  • a simple and effective means of detecting abnormal sleep would aid in identifying those who need further investigation.
  • the present invention provides a method of assessing sleep state of an individual, the method comprising:
  • %TA determining from the time series of accelerometer data a percentage of time in which the individual is substantially immobile
  • the present invention provides a system for assessing sleep state of an individual, the system comprising:
  • an accelerometer device configured to be mounted upon or to the individual and configured to obtain a time series of accelerometer data; and a processor configured to determine from the time series of accelerometer data a percentage of time in which the individual is substantially immobile (%TA), the processor further configured to determine from the time series of accelerometer data a typical time of continuous immobility (MTI); the processor further configured to combine the %TA and MTI to produce a sleep score; and the processor further configured to, if the sleep score exceeds a threshold, output an indication that the individual is asleep.
  • %TA percentage of time in which the individual is substantially immobile
  • MTI typical time of continuous immobility
  • the present invention provides a non-transitory computer readable medium for assessing sleep state of an individual, comprising instructions which, when executed by one or more processors, causes performance of the following:
  • %TA determining from the time series of accelerometer data a percentage of time in which the individual is immobile
  • Some embodiments of the invention may thus provide for measurement of night time sleep using an accelerometry based system suitable for use in a non-clinical setting such as the individual's home.
  • Embodiments of the invention may thus provide a simple means of differentiating between normal and abnormal sleep, including abnormal sleep which is not caused by sleep apnoea.
  • Some embodiments may be applied to assess sleep state of Parkinsonian subjects.
  • Some embodiments may be applied to assess sleep state of non-Parkinsonian subjects.
  • the sleep score may further be generated by summing or otherwise combining 2 or more of a set of sleep-related variables derived from the accelerometer data.
  • the sleep related variables may include a variable reflecting the individual's attempts at being active, such as a "percent of time active" (PTA) variable.
  • PTA percent of time active
  • the sleep related variables may include a variable reflecting the individual's inactivity while awake, such as a "percent of time inactive" (PTIn) variable.
  • the sleep related variables may include a variable reflecting the individual's immobility while asleep, such as a "percent of time immobile” (PTI) variable.
  • PTI percent of time immobile
  • the sleep related variables may include a variable reflecting the individual's Sleep Duration.
  • the sleep related variables may include a variable reflecting the individual's sleep fragment length, such as a "mean fragment length” (MFL) variable.
  • MFL mean fragment length
  • the sleep related variables may include a variable reflecting the individual's Sleep Quality, such as a variable reflecting a proportion of time in a night period in which the individual was very immobile.
  • combining 2 or more of a set of sleep-related variables derived from the accelerometer data may comprise the use of weights and combinatorial algorithms, the weights and algorithms being determined by a machine learning algorithm or the like configured to optimise selectivity and/or sensitivity of assessing a chosen condition.
  • the sleep score is produced only in respect of data obtained during a period of attempted sleep.
  • the period of attempted sleep may be predefined, for example being preprogrammed into the device by a physician or technician.
  • commencement and/or conclusion of the period of attempted sleep may be partly or wholly defined by the individual in substantially real-time, such as by the individual making a user entry at the time of going to bed and/or getting out of bed.
  • the user entry may be facilitated by any suitable user entry device, such as for example an app running on a tablet or smartphone or the like.
  • Figures 1-3 illustrate a means for detection of kinetic state in accordance with an embodiment of the invention
  • Figures 4-6 illustrate the efficacy of the described approach.
  • Figures 7A-7E illustrate sleep state of a control subject
  • FIGS. 8A-8C illustrate sleep state of another control subject
  • Figures 9A-9C illustrate sleep state of a person with Parkinson's
  • Figures 1 OA- IOC illustrate sleep state of another person with Parkinson's
  • FIGS 11 A-l 1H illustrate the relative statistical importance of sleep state variables in differentiating differing sleep states
  • Figures 12A-12I illustrate the relative statistical importance of sleep state variables, and sleep state scores derived therefrom, in differentiating differing sleep states
  • Figures 13A-13I illustrate the correlation of sleep state variables, and sleep state scores derived therefrom, to a clinical standard
  • Figures 14A-14I illustrate the relationship between each variable and the PSG score.
  • Figure 1 is a diagrammatic view of a device 15 for detection of kinetic state during an attempted sleep period of an individual, in accordance with an embodiment of the invention.
  • the device 15 is wrist mounted which the present inventors have recognised provides a sufficiently accurate representation of the kinetic state of the whole body.
  • the device 15 comprises three elements for obtaining movement data of a limb of a person.
  • the device 15 comprises a motion monitor 21 in the form of an accelerometer, a data store 22 for recording the data, and an output means 23 for outputting movement data.
  • the device 15 is a light weight device which is intended to be worn on the wrist of the person as shown in Figure 2.
  • the device is mounted on an elastic wrist band so as to be firmly supported enough that it does not wobble on the arm and therefore does not exaggerate accelerations.
  • the device is configured to rise away from the person's wrist by a minimal amount, or not at all, so as to minimise exaggeration of movements.
  • the device may be on a wrist band secured by a buckle, whereby the act of unbuckling and removing the device breaks a circuit and informs the logger that the device is not being worn.
  • the user preferably wears the device throughout the night or throughout an attempted sleep period of interest. This allows the device to record kinetic activity of the individual for the sleep period.
  • the accelerometer 21 records acceleration in three axes X, Y, Z over the bandwidth 0 - 10Hz, and stores the three channels of data in memory on-board the device.
  • This device has sufficient storage to allow data to be stored on the device for a recording period of up to 12 hours, more preferably 10 days, after which the device can be provided to an administrator for the data to be downloaded and analysed.
  • the device when the device is removed after the recording period, the device is configured to transfer the data to an associated device which then transmits the data via wireless broadband to analysis servers at a central facility (114 in Figure 3).
  • FIG. 3 illustrates kinetic state monitoring and reporting in accordance with one embodiment of the invention.
  • a user 112 is wearing the device of Figures 1 & 2.
  • the device 15 logs accelerometer data and communicates it to a central computing facility 114.
  • the computing facility 114 analyses the data using an algorithm (discussed further below), to obtain a time series of scores for the sleep state of the person 112. These scores are reported to a sleep physician 116 in a format which can be rapidly interpreted by the sleep physician to ensure efficient use of the physician's time.
  • Physician 1 16 interprets the sleep state report and implements or updates a treatment of the user 112 as required.
  • the accelerometer 21 measures acceleration using a uniaxial accelerometer with a measurement range of +/- 4g over a frequency range of 0 to 10 Hz.
  • a triaxial accelerometer can be used to provide greater sensitivity.
  • the PKG score appears to provide a simple means of detecting normal and abnormal sleep in PD. This is based on a small PSG sample.
  • Column 1 of Table 2 contains the score as estimated from the PKG measures in accordance with the present embodiment of the invention. Two values were used to produce a PKG score: The Percent Time Asleep, which is a measure of the proportion of time immobile over the period in which sleep was attempted (akin to sleep efficiency) and the median length (duration) of each period of immobility making up the sleep (akin to a measure of fragmentation). A number of other markers were examined but these two provided a degree of difference between SD and N.
  • Percent Time Asleep was then scored with a level of severity from 1-5 (with 1 being most affected and 5 being normal) based on the median, 75th and 90th percentile of normals (for Percent Time Asleep) as well as the 75th percentile of SD. Median Duration of immobility was then scored with a level of severity from 1-3 (with 1 being most affected and 3 being normal) based on the median and 75th of normal.
  • the next step was to compare the PKG score with the PSG (Table 1, Figure 6). This further confirms that the PKG score is helpful for sorting into "normal” and "abnormal” sleep but not in grading severity further in terms of matching severity by PSG. Note that the sleep abnormalities in the PSG were most severe for OSA and these are not necessarily the reason for having abnormalities of sleep in PD.
  • Figures 7 to 14 illustrate further embodiments of the present invention.
  • normal ranges for the respective scores were obtained from a cohort of 155 subjects aged 60 years or more without known neurodegenerative disorders.
  • the comparison group was 72 PD subjects.
  • the various scores assessed, and their derivation, is as follows.
  • the time period of data recording was divided into periods based on the time of day, as follows.
  • An Active Period (AP) during the hours 09:00-18:00, chosen because most subjects are active and pursuing their usual daily activity in this period.
  • a Night Period (NP) was examined for quality of nocturnal sleep.
  • a Rest Period (RP) during the hours 08:00-23 : 00 was chosen to represent a period when most people are sedentary.
  • a dyskinesia score (DKS, or DK score) is calculated every two minutes throughout the period of time that the logger is worn.
  • DKS is calculated in accordance with the teachings of International Patent Publication Number WO 2009/149520, the content of which is incorporated herein by reference, however in alternative embodiments the DKS may be determined in any suitable alternative manner.
  • Median DKS The median value of the DK scores from the AP.
  • the Median DKS correlates with the Abnormal Involuntary Movement Score assessed at the time of donning the PKG logger.
  • Figure 1 lb shows the Distribution of the median DKS for the control group and the PD Group.
  • Table 3 below sets out the values observed for DKS in each group, in particular being the minimum observed DKS value, the 10 th , 25 th , 75 th and 90 th percentile values of DKS, the Median DKS, and the maximum observed DKS value. It is to be noted that DKS may be measured on any suitable scale, and may be assessed by reference to any suitable division of percentile bands.
  • alternative embodiments of the present invention may use four percentile bands in the manner described in the above-referenced WO 2009/149520, specifically DK I (0-50th percentile of normal) DK II (50 th - 75 th percentile of normal), DK III (75 th - 90 th percentile of normal) and DK IV (>90 th percentile of normal).
  • DK I (0-50th percentile of normal
  • DK II 50 th - 75 th percentile of normal
  • DK III 75 th - 90 th percentile of normal
  • DK IV >90 th percentile of normal
  • a bradykinesia score (BKS, or BK score) is calculated every two minutes throughout the period of time that the logger is worn.
  • BKS is calculated in accordance with the teachings of International Patent Publication Number WO 2009/149520, the content of which is incorporated herein by reference, however in alternative embodiments the BKS may be determined in any suitable alternative manner. It is to be noted that, as for DKS, the BKS may be measured on any suitable scale, and may be assessed by reference to any suitable division of percentile bands. Over each period of analysis (e.g.
  • the BKS can be examined as a frequency histogram of the values for BKS in the manner shown in Figures 7A, 7B, 8 A, 8B, 9A, 9B, 10A and 10B.
  • the present embodiment recognises that the BKS can be grouped into two super categories referred to herein as a Mobile category and an Immobile category, and that each in turn can be further divided into two subcategories, referred to herein as Active Mobile, Inactive Mobile, Moderate Immobile and Very Immobile, as shown in Figure 7A. See Figure 11A for the BKS distribution and Table 3 above for the values observed for BKS in each group.
  • Figure 7A is a histogram of BKS units in a Control (non PD) subject from the Active Period (AP).
  • Figure 7B is a histogram of BKS units in the same subject from the Night Period (NP).
  • the x axis is the value of the BKS unit and the Y axis is the number of BKS units with that value.
  • Each histogram shows the four types of BKS categories: Active (0 ⁇ BKS ⁇ 44), Inactive (44 ⁇ BKX ⁇ 80) and Immobile (80 ⁇ BKS), which is divided into a Moderate Immobile category (80 ⁇ BKS ⁇ 110) and a Very Immobile category (110 ⁇ BKS).
  • the Active 5 o value is defined in this embodiment as being the median (and mode) of the Active BKS during the AP.
  • the distribution of the BKS is shown in red in both histograms. It is noted that the distribution of Active BKS in the night period histogram of Figure 7B is similar to the day period histogram of Figure 7A.
  • the median BKS of 20.4 for the subject of Figure 7 is similar to the Activeso value of 19.6, as is generally the case for normal subjects.
  • Figure 7C is a raster plot of 6 six consecutive days denoted API to AP6, showing data from the AP of each day.
  • Each BKS value is shown as a light blue dot in the top row if the BKS is in the Active range (0-44), or as a dark blue dot in the second row if the BKS is in the Inactive range (44-80), or as a black dot in the third row if the BKS is in the Immobile range (BKS>80).
  • a red dot is shown in the fourth row of each raster trace if at least four of the surrounding consecutive BKS values are >80. Each red dot thus indicates that the surrounding 7 consecutive BKS scores reflect the existence of a "sleep epoch". It is notable in Figure 7C that this subject was awake (ie not immobile) and active (most dots light blue) for most of the AP on each of the 6 days observed.
  • Figure 7D is a raster plot of six consecutive evenings, showing data from 22:00-07:00 but with NP shaded in light grey. Each BKS is coloured and positioned in one of four rows, using the same convention described above in relation to Figure 7C. It is notable in Figure 7D that the BKS data indicate that this subject was active (with blue dots in the top row) until about 01 :00 during night periods NP2 - NP5, and was "asleep" until at least 07:00 during night periods NPl, NP2, NP4 and NP5. On NP6 this subject went to sleep about 3 hours earlier than the other nights and rose shortly after 03 :00, which for example might be indicative of a shift worker.
  • Figure 7E provides an enlarged view of a portion of the raster plot of Figure 7D, illustrating the top row 702 of Active BKS values, the second row 704 of Inactive BKS values, the third row 706 of Immobile BKS values, and the fourth row 708 of sleep epoch data points.
  • Figure 8 shows data obtained from another normal control subject, using the same plotting conventions as Figure 7.
  • Figure 8 A shows a histogram of BKS values from the second control subject during the AP (09:00 - 18:00)
  • Figure 8B shows the BKS values from the P (23 :00 - 06:00).
  • Figure 8C shows that this person falls asleep most nights around 23 :00 and awakes around 06:00 each morning and exhibits relatively normal sleep between those times.
  • Figure 9 shows BKS data obtained from a Person with Parkinson's (PwP).
  • Figure 9A shows that, during the AP, this person exhibits increased Immobile BKS measures.
  • Figure 9B shows that during the NP a markedly abnormal sleep pattern exists. This is revealed by very little BKS in either the very immobile or immobile range as compared to the controls of Figures 7B and 8B. The abnormal sleep is also evidenced in Figure 9B by way of the increased Inactive and active data throughout the record, as compared to the control subjects of Figures 7B & 8B. It is noted that the Activeso is only modestly elevated in the PwP in Figures 9A & 9B, as compared to the Activeso in Figures 7 and 8.
  • Figure 10 shows the data from another PwP. This subject exhibits a marked preponderance of Mobile Inactive BKS Values during the AP, even though there is little Immobility (i.e., little day time sleep).
  • Figure IOC shows that the subject is late retiring, typically falling asleep around 01 :00 - 01 :30.
  • Figure IOC further shows that this subject has reasonably long periods of "sleep" as shown by Sleep epochs in the fourth row of each raster plot.
  • the Moderately Immobile range is when BKS is between 80-110.
  • Day Time Immobility is defined as the percentage of time during the AP with Immobility, and has been correlated with polysomnographic recordings of sleep in the daytime. Immobility during the AP is mainly in the MI range when present in normal subjects ( Figure 7A, 7C and 8 A) and in many patients ( Figure 9A & 10A). Table 3 sets out the normal ranges for PTI as determined from the 155 control subjects and the 72 PD subjects.
  • BKS ⁇ 80 are broadly defined as Mobile. Examination of the Mobile BKS (eg Figure 7A, 7B, 8A and 8B) suggests that there are two distributions within BKS ⁇ 80: a Gaussian distribution typically less than 40-50 BKS and a separate distribution between 40 and 80.
  • Principle Component Analyses (PCA) supported the conclusion that there were indeed two components with BKS ⁇ 80.
  • Figure 10A shows an extreme example of a subject clearly exhibiting the separate distribution of BKS in the 40-80 range, independently of and in addition to the Gaussian distribution of BKS ⁇ 40. Accordingly, this is reflected by the division of Mobile BKS into Active Mobile and Inactive Mobile as shown in Figure 7A.
  • Active BKS are thus BKS measures which fall in the lower Gaussian Distribution.
  • the proportion of BKS within the Active Distribution during the AP is referred to as the Percent Time Active (PTA).
  • PTA Percent Time Active
  • This boundary between Active and Inactive is referred to herein as Boundary A-I. It is to be appreciated that any suitable value may be selected or determined for Boundary A-I.
  • Figure 11 A shows plots of the distribution of median BKS (BKSso), Activeso, and the boundary between Active and Inactive BKS (A-I Boundary) in normal subjects (C) aged greater than 60 and PwP (PD).
  • Figure 1 IB shows plots of the distribution of median DKS (DKSso) in normal subjects (C) aged greater than 60 and PwP (PD).
  • Figure 11C is a plot of the difference between median BKS (BKSso) on the X axis and Activeso on the Y axis showing these values for both Controls (black dots) and PwP (red triangles). In most cases there is a modest reduction in the Activeso but on occasions the reduction is large with higher BKS (eg as shown in Figure 10).
  • All BKS categories (Mobile (Active, Inactive) and Immobile (MI and VI) are used in all periods including AP, RP and P and their percentage time in these categories varies according to which period is being examined (see Table 3 and Figure 11).
  • Figures 1 ID, 1 IE, 1 IF and 11G show the PTA, PTIn and PTI in the AP and NP. As expected PTA is higher in the AP whereas the PTI is higher in the NP. PTI is significantly higher in the day time and lower at night in PwP, compared with controls.
  • PTI In the NP is, in effect, the proportion of time in the NP that the subject was immobile. This correlates with sleep in the day but may not be as good a correlation in the NP because people may move (BKS ⁇ 80) during nocturnal sleep.
  • the range of BKS used in this embodiment extends from values of 1 to 150, and there is progressively less energy in the movement as the scores increase. While BKS scores from 80 to 150 do not reflect precisely zero movement, we define herein that the person has "moved" only if the BKS ⁇ 80, and that for BKS > 80 there exists a range of immobility including both the Immobile and Very Immobile bands.
  • Factors that might be considered in assessing sleep include:
  • Efficiency the extent to which a person slept, throughout the period in which sleep was attempted. This is achieved in the Polysomnography (PSG) lab by measuring time asleep during the period from lights OFF to lights ON. This is difficult at home or otherwise out of the clinical setting with the body worn device of the present invention, because we can only assess when sleep began and not the period over which sleep was attempted (ie in bed and trying to sleep).
  • the choice of the NP being from 23 :00 to 06:00 is made because -75% of subjects were asleep within 30 mins of 23 :00 and >90% slept till 06:00, as shown in Figure 11H.
  • Figure 11H shows the time that control subjects and PwP retired relative to 23 :00 or awoke relative to 06:00.
  • Total as % (right Y axis) refers to the time between first sleep (measured by a train of consecutive sleep epochs: either already asleep at 23 :00 or first appearance after 23 :00) and last sleep (either before or ending at 06:00) expressed as a percent of the 420 available minutes. Even though the resulting NP is less than the "standard 8 hours", most people are asleep over this period (Figure 11G) and so we assess the amount of "sleep" by reference to such a definition of NP by the following estimates. [0073] In all figures bars show the median and interquartile range. These ranges are tabulated in Table 3.
  • PTI This is the proportion of the P in which BKS>80. While it broadly correlates inversely with time between Offset and onset of sleep, in control the PTI is ⁇ 25% lower. The PTI is in effect a measure of sleep efficiency
  • PTIn Subjects who have made movements in their sleep or are awake but attempting sleep, may have BKS ⁇ 80 and in the Inactive range for that subject.
  • Time Awake This is related to a number of factors. This includes those related to poor sleep hygiene (late to bed, early rising): factors related to sleep disruption (pain, bladder control etc.): factors related to mood or disrupted sleep regulation (e.g. early awakening from depression).
  • the premise here is that frank awakening will be captured in part by Active BKS (PTA, as described above) rather than PTIn.
  • PTA Active BKS
  • time Awake will be inversely related to Sleep Efficiency.
  • Step l For a particular individual, give each variable a score ranging from 0-5. This is because each variable has a different range (some percentages (0-100) and others in minutes and less than 30 units) and distribution, so they must be normalised if they are to be summed. To achieve this the 10 th , 25 th , 50 th , 75 th and 90 th percentile of each variable were found and these were used as a scoring system. A score from 0-5 was given according to Table 4. Note Table 4 provides two inverse options for this conversion, depending on whether the assessment should return higher scores to indicate better sleep, or lower scores to indicate better sleep.
  • Step 2 Sum and weight each normalised variable.
  • a Sleep Score for a particular condition eg PD
  • PD a x PTA+ b x PTI + c x, PTIn + x Sleep Duration + e x MFL +/x Sleep Quality
  • weightings that might range from 0 (no weight) to some value greater than 1 (to increase the weight). These weights might be determined by inspection, by trial and error or by using machine learning.
  • Step 3 Determine the weightings for a particular condition.
  • An assumption here is that there already exists a "gold standard” measure of disordered sleep for each condition.
  • PSG is widely held as the Gold standard for sleep but (a) it is commonly reported subjectively (normal/abnormal); (b) it requires admission to a laboratory and so sleep is in unaccustomed settings with imposed sleep regimen; (c) it has scores for periodic limb movements and arousals but is weighted toward sleep apnoea.
  • a common alternative is to use validated patient reported sleep scales.
  • the Epworth sleepiness score (ESS) is an example for day time sleepiness and the Parkinson's Disease Sleep scale - 2 (PDSS 2) is an example for sleep in PD.
  • ESS Epworth sleepiness score
  • PDSS 2 Parkinson's Disease Sleep scale - 2
  • the PDSS 2 is a comprehensive questionnaire that asks about night time sleep patterns and day time sleep patterns. It has the short coming that it is self reported, it covers more than night time sleep and it is non linear. This is important because "normal sleep” receives a score of "0" even though normal sleep has a wide range of variability and the transition from normal to moderate is by an increment of "2" and so also is the transition from moderate to severe (ie not linear).
  • Figures 12 A, B, & C show the values for Controls (C, green dots) and PwP (PD, red dots) for all of the variables used to create a sleep score (SS, in Fig 12 C, right Y axis). These variables are described in the text and are Sleep Duration (A), Median Fragment Length (MFL, Fig 12B), PTI, PTIn, Sleep Quality (Fig 12B). PDSS-2 was obtained by questionnaire for most PwP and Controls and is shown in Figure 12C. In all graphs there was a significant difference between data from Controls and PwP (>0.0001, Mann Whitney). The differences between Controls and PwP were statistically different and with meaningful effect size. In Summary, PwP spent more time awake but Inactive, less time Immobile and with Shorter Sleep Duration.
  • PDSS 2 is a recognised Sleep Scale. While it is not expected that there will be very high correlation between each variable and the PDSS 2 they should each have a relevant trend if they are likely to influence a Weighted Sleep Score.
  • Each Variable was compared with the PDSS 2 ( Figure 13A-F, in which circular data points are controls and square data points are PwP).
  • Figure 13 A shows the relationship between Sleep Score and PDSS-2. The relationship is not significant.
  • Figures 13 B, C, D, F & G show the relationship between PDSS 2 and each subcomponent of the Sleep Score.
  • WSS a x PTA+ b x PTI + c x, PTIn + d x Sleep Duration + e x MFL + f x Sleep
  • WSS Weighted Sleep Score [0095] WSS C was produced because Sleep Quality and Duration both showed a Good relationship with PDSS 2. WSS B was produced because it was developed for testing against PSG.
  • BKS has ranges (at least four). Immobility induced by sleep is more than just "still” measured by a higher BKS but includes various grades of two or more levels of "stillness” as measured by a higher BKS. Quality of sleep has a relationship to the extent of "stillness” measured by a higher BKS. We believe that this is related to the architecture of sleep.
  • Fragmentation is a measure of poor sleep.
  • the length of passage of immobility as measured by the number of consecutive BKS that are greater than some specified BKS value (eg 80 or 110) indicates better sleep.
  • the total duration of sleep (using various analyses of BKS to find a total amount of immobility in a specified period of attempted sleep) is a measure of the quality of sleep.
  • the amount of time with "Active" BKS indicates movements during a night period that suggest either that sleep is not being attempted (poor sleep hygiene) or that movements are intruding into and disrupting sleep (eg REM sleep disorder).
  • the amount of "Inactive" BKS indicates movements during a night period that suggest either that sleep is being attempted but not achieved (insomnia) or that movements are intruding into and disrupting sleep (eg micro-arousals and periodic limb movements).
  • Reference herein to a "module” may be to a hardware or software structure which is part of a broader structure, and which receives, processes, stores and/or outputs communications or data in an interconnected manner with other system components in order to effect the described functionality.
  • Some embodiments of the invention may employ kinetic state or sleep state assessment in accordance with any or all of the teaching of International Patent Publication No. WO 2009/149520 by the present applicant, the content of which is incorporated herein by reference.
  • accelerometry using the Parkinson Kineti graph can be used to distinguish between normal and abnormal sleep in Parkinson's Disease (PD)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Artificial Intelligence (AREA)
  • Signal Processing (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Psychiatry (AREA)
  • Fuzzy Systems (AREA)
  • Mathematical Physics (AREA)
  • Evolutionary Computation (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Anesthesiology (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Disabilities (AREA)

Abstract

L'invention concerne l'évaluation de l'état du sommeil d'un individu. Une série temporelle de données d'accéléromètre est obtenue à partir d'un dispositif d'accéléromètre monté sur l'individu. A partir de la série temporelle de données d'accéléromètre, un pourcentage de temps pendant lequel l'individu est sensiblement immobile (% TA) est déterminé. A partir de la série temporelle de données d'accéléromètre, une durée typique d'immobilité continue (MTI) est également déterminée. Le % TA et la MTI sont combinés par exemple par somme pondérée, pour produire un score de sommeil. Si le score de sommeil dépasse un seuil, cela indique que l'individu est endormi.
PCT/AU2017/050015 2016-01-07 2017-01-09 Système et procédé d'évaluation de l'état du sommeil WO2017117636A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2017204960A AU2017204960A1 (en) 2016-01-07 2017-01-09 System and method for assessing sleep state
US16/068,183 US20190008451A1 (en) 2016-01-07 2017-01-09 System and Method for Assessing Sleep State
CN201780009611.4A CN108697379A (zh) 2016-01-07 2017-01-09 用于评估睡眠状态的系统和方法
CA3010346A CA3010346A1 (fr) 2016-01-07 2017-01-09 Systeme et procede d'evaluation de l'etat du sommeil
EP17735774.6A EP3399912B1 (fr) 2016-01-07 2017-01-09 Système et procédé d'évaluation de l'état du sommeil
JP2018535025A JP2019505291A (ja) 2016-01-07 2017-01-09 睡眠状態を評価するためのシステム及び方法
AU2021266231A AU2021266231A1 (en) 2016-01-07 2021-11-09 System and method for assessing sleep state

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016900036 2016-01-07
AU2016900036A AU2016900036A0 (en) 2016-01-07 System and Method for Assessing Sleep State

Publications (1)

Publication Number Publication Date
WO2017117636A1 true WO2017117636A1 (fr) 2017-07-13

Family

ID=59273094

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2017/050015 WO2017117636A1 (fr) 2016-01-07 2017-01-09 Système et procédé d'évaluation de l'état du sommeil

Country Status (7)

Country Link
US (1) US20190008451A1 (fr)
EP (1) EP3399912B1 (fr)
JP (1) JP2019505291A (fr)
CN (1) CN108697379A (fr)
AU (2) AU2017204960A1 (fr)
CA (1) CA3010346A1 (fr)
WO (1) WO2017117636A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108606796A (zh) * 2018-04-16 2018-10-02 漳州市恒丽电子有限公司 一种莫比乌斯环表
JP2019170408A (ja) * 2018-03-26 2019-10-10 パナソニックＩｐマネジメント株式会社 サポートシステム、機器制御システム、推定方法、及び、機器制御方法
WO2019218010A1 (fr) * 2018-05-17 2019-11-21 Global Kinetics Pty Ltd Système de détermination de la progression de la maladie de parkinson
US11324950B2 (en) 2016-04-19 2022-05-10 Inspire Medical Systems, Inc. Accelerometer-based sensing for sleep disordered breathing (SDB) care

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11399636B2 (en) * 2019-04-08 2022-08-02 Sleep Number Corporation Bed having environmental sensing and control features
CN112168139B (zh) * 2019-07-05 2022-09-30 腾讯科技（深圳）有限公司 一种健康监控方法、装置及存储介质
EP4003497A1 (fr) 2019-07-25 2022-06-01 Inspire Medical Systems, Inc. Systèmes et procédés pour faire fonctionner un dispositif médical implantable sur la base d'informations de postures détectées

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087878A1 (en) * 2002-11-01 2004-05-06 Individual Monitoring Systems, Inc. Sleep scoring apparatus and method
US20140364770A1 (en) * 2013-06-06 2014-12-11 Motorola Mobility Llc Accelerometer-based sleep analysis
WO2015118534A1 (fr) * 2014-02-04 2015-08-13 The Medical Research Fund At The Tel-Aviv Sourasky Medical Center Procédés et systèmes de diagnostic ou de pronostic de la maladie de parkinson à l'aide de capteurs fixés au corps

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1163878A1 (fr) * 2000-06-15 2001-12-19 The Procter & Gamble Company Dispositif pour mesurer l' activité du corps et procédé
US20060020178A1 (en) * 2002-08-07 2006-01-26 Apneos Corp. System and method for assessing sleep quality
ATE529156T1 (de) * 2003-08-18 2011-11-15 Cardiac Pacemakers Inc System und verfahren zum umgang mit atemstörungen
JP4825586B2 (ja) * 2006-05-30 2011-11-30 東芝コンシューマエレクトロニクス・ホールディングス株式会社 睡眠モニタ装置
EP2020919B1 (fr) * 2006-06-01 2019-07-31 ResMed Sensor Technologies Limited Appareil, système et procédé de surveillance de signaux physiologiques
WO2008037020A1 (fr) * 2006-09-27 2008-04-03 Resmed Ltd Procédé et appareil d'évaluation de la qualité du sommeil
CA2727555C (fr) * 2008-06-12 2016-10-04 Global Kinetics Corporation Pty Ltd Detection d'etats d'hypocinesie et/ou d'hypercinesie
CN102068260B (zh) * 2009-11-25 2013-06-05 深圳市健康鼠科技有限公司 睡眠质量监测方法以及生活方式管理建议系统
KR101218626B1 (ko) * 2010-10-29 2013-01-07 아주대학교산학협력단 수면의 질 결정 장치 및 방법
US8568330B2 (en) * 2011-03-08 2013-10-29 Pulsaw Informatics, Inc. Composite human physiological stress index based on heart beat and sleep and/or activity history data including actigraphy
EP2524647A1 (fr) * 2011-05-18 2012-11-21 Alain Gilles Muzet Système et procédé de détermination des étapes de sommeil d'une personne
WO2015006364A2 (fr) * 2013-07-08 2015-01-15 Resmed Sensor Technologies Limited Procédé et système pour la gestion du sommeil
JP2015097612A (ja) * 2013-11-19 2015-05-28 キッセイコムテック株式会社 動作障害がある疾患の症状評価方法および症状評価システム、ならびに症状評価プログラム
WO2015107681A1 (fr) * 2014-01-17 2015-07-23 任天堂株式会社 Système de traitement d'informations, serveur de traitement d'informations, programme de traitement d'informations et procédé de fourniture d'informations
US9808185B2 (en) * 2014-09-23 2017-11-07 Fitbit, Inc. Movement measure generation in a wearable electronic device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087878A1 (en) * 2002-11-01 2004-05-06 Individual Monitoring Systems, Inc. Sleep scoring apparatus and method
US20140364770A1 (en) * 2013-06-06 2014-12-11 Motorola Mobility Llc Accelerometer-based sleep analysis
WO2015118534A1 (fr) * 2014-02-04 2015-08-13 The Medical Research Fund At The Tel-Aviv Sourasky Medical Center Procédés et systèmes de diagnostic ou de pronostic de la maladie de parkinson à l'aide de capteurs fixés au corps

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BHIDAYASIRI ET AL.: "Capturing Nighttime Symptoms in Parkinson Disease: Technical Development and Experimental Verification of Inertial Sensors for Nocturnal Hypokinesia", JRRD, vol. 53, no. 4, 1 January 2016 (2016-01-01), pages 487 - 498, XP055570813, DOI: 10.1682/JRRD.2015.04.0062 *
JENNIFER GIRSCHIK ET AL.: "Validation of Self-Reported Sleep Against Actigraphy", JOURNAL OF EPIDEMIOLOGY, vol. 22, no. 5, 28 July 2012 (2012-07-28), pages 462 - 468, XP055583208, DOI: 10.2188/jea.JE20120012
MAGLIONE ET AL.: "Actigraphy for the Assessment of Sleep Measures in Parkinson's Disease", SLEEP, vol. 36, no. 8, 1 August 2013 (2013-08-01), pages 1209 - 1217, XP055396526 *
PAN ET AL., QUANTITATIVE EVALUATION OF THE USE OF ACTIGRAPHY FOR NEUROLOGICAL AND PSYCHIATRIC DISORDERS BEHAVIOURAL NEUROLOGY, vol. 2014, 19 August 2014 (2014-08-19), XP055396530 *
STAVITSKY ET AL.: "Parkinsonism and related disorders", vol. 16, 1 May 2010, ELSEVIER SCIENCE, article "Sleep in Parkinson's disease: A comparison of actigraphy and subjective measures", pages: 280 - 283

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324950B2 (en) 2016-04-19 2022-05-10 Inspire Medical Systems, Inc. Accelerometer-based sensing for sleep disordered breathing (SDB) care
JP2019170408A (ja) * 2018-03-26 2019-10-10 パナソニックＩｐマネジメント株式会社 サポートシステム、機器制御システム、推定方法、及び、機器制御方法
JP7432884B2 (ja) 2018-03-26 2024-02-19 パナソニックＩｐマネジメント株式会社 サポートシステム、機器制御システム、サポートシステムの作動方法、及び、機器制御システムの作動方法
CN108606796A (zh) * 2018-04-16 2018-10-02 漳州市恒丽电子有限公司 一种莫比乌斯环表
WO2019218010A1 (fr) * 2018-05-17 2019-11-21 Global Kinetics Pty Ltd Système de détermination de la progression de la maladie de parkinson

Also Published As

Publication number Publication date
CA3010346A1 (fr) 2017-07-13
EP3399912B1 (fr) 2022-04-13
EP3399912A4 (fr) 2019-06-05
CN108697379A (zh) 2018-10-23
AU2017204960A1 (en) 2018-08-23
EP3399912A1 (fr) 2018-11-14
AU2021266231A1 (en) 2021-12-02
US20190008451A1 (en) 2019-01-10
JP2019505291A (ja) 2019-02-28

Similar Documents

Publication Publication Date Title
EP3399912B1 (fr) Système et procédé d'évaluation de l'état du sommeil
Zinkhan et al. Agreement of different methods for assessing sleep characteristics: a comparison of two actigraphs, wrist and hip placement, and self-report with polysomnography
Kosmadopoulos et al. Alternatives to polysomnography (PSG): a validation of wrist actigraphy and a partial-PSG system
Schwarz et al. Age affects sleep microstructure more than sleep macrostructure
Elrod et al. Sleep differences among children with autism spectrum disorders and typically developing peers: a meta-analysis
CN107106085B (zh) 用于睡眠监测的设备和方法
US10244977B2 (en) System and method for early detection of mild traumatic brain injury
JP6208372B2 (ja) うつ状態判別方法、及びうつ状態判定装置
Wang et al. Validation of the rapid eye movement sleep behavior disorder screening questionnaire in China
AU2019202928A1 (en) Monitoring the effects of sleep deprivation using neuronal avalanches
CA3070980A1 (fr) Procedes et systemes pour prevoir des crises d'epilepsie
Duce et al. The AASM recommended and acceptable EEG montages are comparable for the staging of sleep and scoring of EEG arousals
US20160100792A1 (en) Sleep state determination apparatus, sleep state determination method, and sleep management system
US20170065199A1 (en) Monitoring human brain excitability using synchronization measures
Levendowski et al. Retrospective cross-validation of automated sleep staging using electroocular recording in patients with and without sleep disordered breathing
Hamida et al. A novel insomnia identification method based on Hjorth parameters
Basner et al. Critical appraisal of methods for the assessment of noise effects on sleep
Kagawa et al. Sleep stage classification by body movement index and respiratory interval indices using multiple radar sensors
JPWO2018221750A1 (ja) 睡眠判定装置、睡眠判定方法、および、睡眠判定プログラム
CN112930139A (zh) 分析睡眠呼吸障碍事件的系统和方法
JP6813837B2 (ja) 活動リズム判定方法および活動リズム判定装置
Pino et al. Validation of non-invasive monitoring device to evaluate sleep quality
Oz et al. Monitoring sleep stages with a soft electrode array: Comparison against vPSG and home‐based detection of REM sleep without atonia
Ohisa et al. A novel EEG index for evaluating the sleep quality in patients with obstructive sleep apnea-hypopnea syndrome
Kawasaki et al. Evaluation of sleep parameters and sleep staging (slow wave sleep) in athletes by fitbit alta HR, a consumer sleep tracking device

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17735774

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3010346

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018535025

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 260439

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2017735774

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017204960

Country of ref document: AU

Date of ref document: 20170109

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017735774

Country of ref document: EP

Effective date: 20180807